Poxel reports positive top-line results for Imeglimin phase 3 trial in Japan

Image: Poxel and Sumitomo Dainippon Pharma announce positive top-line results for Imeglimin Phase 3 Trial (TIMES 1) in Japan for the treatment of type 2 diabetes. Photo: courtesy of mwooten/Pixabay.